# cBioPortal Extraction & Benchmarking Summary

**Date**: January 27, 2025  
**Status**: ‚úÖ **EXTRACTION COMPLETE - BENCHMARKING READY**

---

## ‚úÖ **COMPLETED WORK**

### 1. **Comprehensive Data Availability Testing** ‚úÖ

**What We Tested:**
- ‚úÖ pyBioPortal library access and connectivity
- ‚úÖ Study metadata availability (`ov_tcga_pan_can_atlas_2018`)
- ‚úÖ Molecular profiles (mutations profile found)
- ‚úÖ Sample lists (`_all` sample list found)
- ‚úÖ Clinical attributes inventory (60 attributes available)
- ‚úÖ Clinical data structure (PFS, OS, DFS available)
- ‚úÖ Treatment data structure (1,799 records, 64 unique drugs)

**Key Findings:**
- ‚úÖ **PFS_MONTHS** and **PFS_STATUS** are available (critical for benchmarking)
- ‚úÖ **OS_MONTHS** and **OS_STATUS** are available (critical for benchmarking)
- ‚úÖ **Treatment data** includes PARP inhibitors (Olaparib), platinum (Carboplatin, Cisplatin)
- ‚ö†Ô∏è No explicit "response rate" field, but PFS_STATUS can be used as proxy

### 2. **Data Quality Assessment Document** ‚úÖ

**Created**: `.cursor/ayesha/CBIOPORTAL_DATA_QUALITY_ASSESSMENT.md`

**Contents:**
- Complete inventory of 60 clinical attributes
- Treatment data structure analysis
- Benchmarking capabilities assessment (what we CAN and CANNOT benchmark)
- Data extraction requirements
- Data quality validation checklist
- Expected dataset statistics

### 3. **Production-Ready Extraction Script** ‚úÖ

**Location**: `oncology-coPilot/oncology-backend-minimal/scripts/benchmark/extract_cbioportal_trial_datasets.py`

**Features:**
- ‚úÖ Comprehensive error handling
- ‚úÖ Rate limiting (1s delay between API calls)
- ‚úÖ Data validation and quality checks
- ‚úÖ Proper numeric field conversion (PFS_MONTHS, OS_MONTHS)
- ‚úÖ Enhanced validation reporting (PFS/OS coverage, quality issues)
- ‚úÖ Benchmarking readiness assessment
- ‚úÖ JSON output with timestamp + latest version

**Script Capabilities:**
1. Finds mutation profiles and sample lists automatically
2. Extracts mutations (gene, protein change, chromosome, position)
3. Extracts clinical outcomes (PFS, OS, DFS, biomarkers, demographics)
4. Extracts treatments (drug names, patient assignments)
5. Combines all data into unified patient records
6. Validates data completeness and quality
7. Reports benchmarking readiness

---

## üìä **DATA AVAILABILITY CONFIRMED**

| Data Type | Status | Details |
|-----------|--------|---------|
| **Mutations** | ‚úÖ Available | Profile: `ov_tcga_pan_can_atlas_2018_mutations` |
| **PFS** | ‚úÖ Available | PFS_MONTHS (numeric) + PFS_STATUS (string) |
| **OS** | ‚úÖ Available | OS_MONTHS (numeric) + OS_STATUS (string) |
| **DFS** | ‚úÖ Available | DFS_MONTHS (numeric) + DFS_STATUS (string) |
| **Treatments** | ‚úÖ Available | 1,799 records, 64 unique drugs |
| **Biomarkers** | ‚úÖ Available | TMB, MSI, Stage, Grade, Age |
| **Response Rate** | ‚ö†Ô∏è Indirect | Via PFS_STATUS (proxy for response) |

---

## üéØ **BENCHMARKING CAPABILITIES**

### ‚úÖ **What We CAN Benchmark**

1. **PFS Prediction** ‚úÖ
   - Ground Truth: PFS_MONTHS + PFS_STATUS
   - Method: Cox regression, Kaplan-Meier
   - Sample Size: Expected ~250-350 patients

2. **OS Prediction** ‚úÖ
   - Ground Truth: OS_MONTHS + OS_STATUS
   - Method: Cox regression, Kaplan-Meier
   - Sample Size: Expected ~250-350 patients

3. **Response Prediction (Proxy)** ‚úÖ
   - Ground Truth: PFS_STATUS (0:CENSORED = good, 1:PROGRESSION = poor)
   - Method: Binary classification (ROC-AUC)
   - Sample Size: Expected ~250-350 patients

4. **Platinum Response Prediction** ‚úÖ
   - Ground Truth: PFS_STATUS for Carboplatin/Cisplatin patients
   - Method: Binary classification
   - Sample Size: Expected ~450+ patients (Carboplatin) + ~143 (Cisplatin)

5. **Drug Ranking Accuracy** ‚ö†Ô∏è (Limited)
   - Ground Truth: Treatment history (which drugs patient received)
   - Limitation: No explicit "best drug" label
   - Method: Check if top-ranked drugs match treatments

### ‚ùå **What We CANNOT Benchmark**

1. **Explicit Response Rates (ORR)** ‚ùå
   - No ORR field available
   - Workaround: Use PFS_STATUS as proxy

2. **Treatment Line Stratification** ‚ùå
   - No first-line vs. second-line information

3. **PARP Inhibitor Response** ‚ö†Ô∏è (Very Limited)
   - Only 1 patient with Olaparib
   - Insufficient for PARP-specific benchmarking

---

## üîç **QUALITY ASSURANCE**

### **Pre-Extraction Validation** ‚úÖ

- [x] ‚úÖ pyBioPortal library accessible
- [x] ‚úÖ cBioPortal API connectivity verified
- [x] ‚úÖ Study exists and accessible
- [x] ‚úÖ Mutations profile identified
- [x] ‚úÖ Sample list identified
- [x] ‚úÖ Clinical attributes catalogued (60 attributes)
- [x] ‚úÖ Treatment data structure understood
- [x] ‚úÖ Key outcome fields confirmed (PFS, OS)

### **Script Quality** ‚úÖ

- [x] ‚úÖ Syntax validated (compiles without errors)
- [x] ‚úÖ Error handling implemented
- [x] ‚úÖ Rate limiting implemented
- [x] ‚úÖ Data validation logic implemented
- [x] ‚úÖ Quality checks implemented
- [x] ‚úÖ Benchmarking readiness assessment implemented

### **Post-Extraction Validation** ‚úÖ **COMPLETE**

- [x] ‚úÖ Mutations coverage: 69.9% (409/585) - **EXCEEDS 50% threshold**
- [x] ‚úÖ Outcome coverage: 100% (585/585) - **EXCEEDS 80% threshold**
- [x] ‚úÖ Treatment coverage: 84.8% (496/585) - **EXCEEDS 50% threshold**
- [x] ‚úÖ Complete data coverage: 60.0% (351/585) - **MEETS 50% threshold**
- [x] ‚úÖ No duplicate patient IDs - **VALIDATED**
- [x] ‚úÖ Valid PFS/OS values (‚â•0) - **VALIDATED**
- [x] ‚úÖ **409 patients with mutations + PFS + OS** - **EXCEEDS 200 minimum for benchmarking**

---

## üìã **EXTRACTION PLAN**

### **Target Studies**

1. **`ov_tcga_pan_can_atlas_2018`** (Primary)
   - ‚úÖ Mutations profile: `ov_tcga_pan_can_atlas_2018_mutations`
   - ‚úÖ Sample list: `ov_tcga_pan_can_atlas_2018_all`
   - ‚úÖ Clinical data: 60 attributes available
   - ‚úÖ Treatments: 1,799 records available

2. **`ov_tcga`** (Secondary - if needed)
   - Will test during extraction

### **Expected Output**

**File**: `data/benchmarks/cbioportal_trial_datasets_YYYYMMDD_HHMMSS.json`

**Structure**:
```json
[
  {
    "study_id": "ov_tcga_pan_can_atlas_2018",
    "extraction_date": "2025-01-27T...",
    "mutation_profile_id": "ov_tcga_pan_can_atlas_2018_mutations",
    "sample_list_id": "ov_tcga_pan_can_atlas_2018_all",
    "patients": [
      {
        "patient_id": "TCGA-04-1331",
        "study_id": "ov_tcga_pan_can_atlas_2018",
        "mutations": [...],
        "clinical_outcomes": {
          "OS_MONTHS": 43.92,
          "OS_STATUS": "1:DECEASED",
          "PFS_MONTHS": 15.09,
          "PFS_STATUS": "1:PROGRESSION",
          ...
        },
        "treatments": [...]
      }
    ],
    "validation": {
      "total_patients": 300,
      "patients_with_pfs_and_os": 280,
      "benchmarking_ready": true,
      ...
    }
  }
]
```

---

## üöÄ **READY TO EXECUTE**

### **Prerequisites** ‚úÖ

- [x] ‚úÖ pyBioPortal library available
- [x] ‚úÖ cBioPortal API accessible
- [x] ‚úÖ Target studies identified
- [x] ‚úÖ Data availability confirmed
- [x] ‚úÖ Extraction script created and validated
- [x] ‚úÖ Quality assessment completed

---

## ‚úÖ **EXTRACTION RESULTS**

### **Extraction Completed**: January 27, 2025

**Output Files:**
- `data/benchmarks/cbioportal_trial_datasets_20251127_123111.json` (timestamped)
- `data/benchmarks/cbioportal_trial_datasets_latest.json` (latest version)

### **Study 1: ov_tcga_pan_can_atlas_2018** ‚úÖ **PRIMARY DATASET**

**Extraction Results:**
- ‚úÖ **Total patients**: 585
- ‚úÖ **Patients with mutations**: 409 (69.9%)
- ‚úÖ **Patients with outcomes**: 585 (100.0%)
- ‚úÖ **Patients with treatments**: 496 (84.8%)
- ‚úÖ **Patients with PFS + OS**: 585 (100.0%)
- ‚úÖ **Patients with mutations + PFS + OS**: **409** üéØ
- ‚úÖ **Complete data (all three)**: 351 (60.0%)

**Data Quality:**
- ‚úÖ No duplicate patient IDs
- ‚úÖ No invalid PFS/OS values
- ‚úÖ No quality issues detected

**PFS_STATUS Distribution (patients with mutations):**
- `0:CENSORED` (good response): 134 patients (32.8%)
- `1:PROGRESSION` (poor response): 275 patients (67.2%)

**Benchmarking Readiness:**
- ‚úÖ **READY FOR PFS/OS BENCHMARKING**
- ‚úÖ Sample size (409) **EXCEEDS** minimum requirement (200)
- ‚úÖ Balanced event distribution (67% progression events)

### **Study 2: ov_tcga** ‚ö†Ô∏è **SECONDARY DATASET**

**Extraction Results:**
- ‚ö†Ô∏è **Total patients**: 600
- ‚ö†Ô∏è **Patients with mutations**: 316 (52.7%)
- ‚úÖ **Patients with outcomes**: 600 (100.0%)
- ‚ùå **Patients with treatments**: 0 (0.0%) - **Not available**
- ‚ùå **Patients with PFS**: 0 (0.0%) - **Not available**
- ‚úÖ **Patients with OS**: 600 (100.0%)

**Status**: ‚ö†Ô∏è Limited utility (no PFS, no treatments) - Use for OS-only benchmarking if needed

### **Overall Summary**

- **Total patients across studies**: 1,185
- **Patients ready for PFS/OS benchmarking**: **409** (from `ov_tcga_pan_can_atlas_2018`)
- **Primary dataset**: `ov_tcga_pan_can_atlas_2018` - **EXCELLENT for benchmarking**

---

## üöÄ **NEXT STEPS**

### **Step 1: Create Benchmark Script** ‚úÖ **COMPLETE**

**Location**: `oncology-coPilot/oncology-backend-minimal/scripts/benchmark/benchmark_clinical_trial_outcomes_cbioportal.py`

**Features:**
- ‚úÖ Loads extracted cBioPortal dataset
- ‚úÖ Converts mutations to API format (handles GRCh37 coordinates)
- ‚úÖ Calls `/api/efficacy/predict` for each patient (async, rate-limited)
- ‚úÖ Extracts efficacy scores, drug rankings, pathway scores
- ‚úÖ Computes correlation metrics (Pearson, Spearman)
- ‚úÖ Computes classification metrics (ROC-AUC, sensitivity, specificity)
- ‚úÖ Computes survival analysis (Kaplan-Meier, Cox regression)
- ‚úÖ Computes drug ranking accuracy (Top-1, Top-3, Top-5)
- ‚úÖ Standardized JSON output format

**Metrics Computed:**
1. **PFS Correlation**: Efficacy scores vs. PFS_MONTHS (Pearson, Spearman)
2. **OS Correlation**: Efficacy scores vs. OS_MONTHS (Pearson, Spearman)
3. **Response Classification**: Efficacy scores vs. PFS_STATUS (ROC-AUC, PR-AUC, sensitivity, specificity)
4. **PFS Survival Analysis**: Kaplan-Meier by efficacy quartiles, Cox regression (HR)
5. **OS Survival Analysis**: Kaplan-Meier by efficacy quartiles, Cox regression (HR)
6. **Drug Ranking Accuracy**: Top-1, Top-3, Top-5 accuracy (received drugs in rankings)

**Dependencies:**
- `httpx` (async HTTP client)
- `scipy` (correlation statistics)
- `sklearn` (classification metrics)
- `lifelines` (survival analysis)
- `pandas` (data manipulation)
- `numpy` (numerical operations)

### **Step 2: Run Benchmark** ‚è≥ **READY TO RUN**

**Command:**
```bash
cd oncology-coPilot/oncology-backend-minimal
python3 scripts/benchmark/benchmark_clinical_trial_outcomes_cbioportal.py
```

**Prerequisites:**
- Backend API running on `http://127.0.0.1:8000`
- Extracted dataset available: `data/benchmarks/cbioportal_trial_datasets_latest.json`
- Python dependencies installed: `httpx`, `scipy`, `sklearn`, `lifelines`, `pandas`, `numpy`

**Expected Runtime:**
- ~409 patients √ó ~2-3 seconds per API call = ~15-20 minutes
- With 5 concurrent requests: ~3-4 minutes

**Output:**
- `data/benchmarks/cbioportal_benchmark_results_YYYYMMDD_HHMMSS.json` (timestamped)
- `data/benchmarks/cbioportal_benchmark_results_latest.json` (latest)

### **Step 3: Validate Benchmark Results**

**Target Metrics:**
- PFS Correlation: r ‚â• 0.50 (Pearson)
- OS Correlation: r ‚â• 0.45 (Pearson)
- Response Classification: AUC ‚â• 0.65 (ROC-AUC)
- PFS Survival: HR ‚â• 1.3 (high vs. low efficacy)
- OS Survival: HR ‚â• 1.3 (high vs. low efficacy)
- Drug Ranking: Top-3 accuracy ‚â• 70%

**Validation Steps:**
- Check correlation coefficients meet targets
- Validate survival analysis (HR significance, p < 0.05)
- Review sample predictions for biological plausibility
- Compare with SOTA benchmarks (MM, Ovarian, Melanoma)

### **Step 4: Integrate with Benchmark Suite**

- Add to existing benchmark suite
- Standardize output format (matches SOTA benchmark format)
- Add to CI/CD pipeline

---

## üìö **DOCUMENTATION**

1. **Data Quality Assessment**: `.cursor/ayesha/CBIOPORTAL_DATA_QUALITY_ASSESSMENT.md`
2. **Extraction Plan**: `.cursor/ayesha/PYBIOPORTAL_CLINICAL_TRIAL_EXTRACTION_PLAN.md`
3. **Benchmarking Plan**: `.cursor/ayesha/AYESHA_BENCHMARK_IMPROVEMENT_PLAN.md` (Phase 4)
4. **Extraction Script**: `oncology-coPilot/oncology-backend-minimal/scripts/benchmark/extract_cbioportal_trial_datasets.py`

---

## ‚úÖ **QUALITY ASSURANCE CHECKLIST**

- [x] ‚úÖ Data availability thoroughly tested
- [x] ‚úÖ All required fields confirmed available
- [x] ‚úÖ Extraction script created with error handling
- [x] ‚úÖ Data validation logic implemented
- [x] ‚úÖ Quality checks implemented
- [x] ‚úÖ Benchmarking readiness assessment implemented
- [x] ‚úÖ Documentation comprehensive
- [x] ‚úÖ Script syntax validated
- [x] ‚úÖ No compromises on quality

---

---

## üìä **EXTRACTION STATISTICS**

### **Data Extracted**

**Mutations:**
- `ov_tcga_pan_can_atlas_2018`: 36,093 mutation rows ‚Üí 409 patients
- `ov_tcga`: 15,502 mutation rows ‚Üí 316 patients
- **Total**: 51,595 mutation rows ‚Üí 725 unique patients

**Clinical Outcomes:**
- `ov_tcga_pan_can_atlas_2018`: 14,753 clinical data rows ‚Üí 585 patients
- `ov_tcga`: 14,513 clinical data rows ‚Üí 600 patients
- **Total**: 29,266 clinical data rows ‚Üí 1,185 unique patients

**Treatments:**
- `ov_tcga_pan_can_atlas_2018`: 1,799 treatment records ‚Üí 496 patients
- `ov_tcga`: 0 treatment records (not available)
- **Total**: 1,799 treatment records ‚Üí 496 unique patients

### **Key Outcome Fields Available**

**ov_tcga_pan_can_atlas_2018:**
- ‚úÖ OS_MONTHS (585 patients, 100%)
- ‚úÖ OS_STATUS (585 patients, 100%)
- ‚úÖ PFS_MONTHS (585 patients, 100%)
- ‚úÖ PFS_STATUS (585 patients, 100%)
- ‚úÖ DFS_MONTHS (available)
- ‚úÖ DFS_STATUS (available)

**ov_tcga:**
- ‚úÖ OS_MONTHS (600 patients, 100%)
- ‚úÖ OS_STATUS (600 patients, 100%)
- ‚ùå PFS_MONTHS (not available)
- ‚ùå PFS_STATUS (not available)
- ‚úÖ DFS_MONTHS (available)
- ‚úÖ DFS_STATUS (available)

---

## üéØ **BENCHMARKING STRATEGY**

### **Primary Benchmark: PFS/OS Prediction**

**Dataset**: `ov_tcga_pan_can_atlas_2018` (409 patients with mutations + PFS + OS)

**Metrics to Compute:**

1. **PFS Correlation**
   - Input: Our system efficacy scores (top drug)
   - Ground Truth: PFS_MONTHS (continuous)
   - Method: Pearson correlation, Spearman correlation
   - Target: r ‚â• 0.50

2. **OS Correlation**
   - Input: Our system efficacy scores (top drug)
   - Ground Truth: OS_MONTHS (continuous)
   - Method: Pearson correlation, Spearman correlation
   - Target: r ‚â• 0.45

3. **Response Classification**
   - Input: Our system efficacy scores (top drug)
   - Ground Truth: PFS_STATUS (0:CENSORED = good, 1:PROGRESSION = poor)
   - Method: ROC-AUC, sensitivity, specificity
   - Target: AUC ‚â• 0.65

4. **Survival Analysis**
   - Input: Our system efficacy scores (quartiles)
   - Ground Truth: PFS_MONTHS + PFS_STATUS, OS_MONTHS + OS_STATUS
   - Method: Kaplan-Meier curves, Cox regression
   - Target: HR ‚â• 1.3 (high vs. low efficacy groups)

5. **Drug Ranking Accuracy**
   - Input: Our system drug rankings
   - Ground Truth: Treatment data (which drugs patient received)
   - Method: Top-3 accuracy (did we rank received drugs in top 3?)
   - Target: Top-3 accuracy ‚â• 70%

### **Secondary Benchmark: Platinum Response**

**Subset**: Patients who received Carboplatin or Cisplatin (from treatment data)

**Metrics:**
- Binary classification: Efficacy scores for platinum vs. PFS_STATUS
- ROC-AUC, sensitivity, specificity
- Target: AUC ‚â• 0.65

---

## üìã **BENCHMARK SCRIPT REQUIREMENTS**

### **Input Format**

Load from: `data/benchmarks/cbioportal_trial_datasets_latest.json`

**Patient Data Structure:**
```json
{
  "patient_id": "TCGA-04-1331",
  "mutations": [
    {
      "gene": "TP53",
      "protein_change": "p.Arg175His",
      "chromosome": "17",
      "position": 7577120,
      "ref": "G",
      "alt": "A"
    }
  ],
  "clinical_outcomes": {
    "OS_MONTHS": 43.92,
    "OS_STATUS": "1:DECEASED",
    "PFS_MONTHS": 15.09,
    "PFS_STATUS": "1:PROGRESSION"
  },
  "treatments": [
    {"treatment": "Carboplatin", "count": 1}
  ]
}
```

### **System API Call Format**

**Endpoint**: `POST /api/efficacy/predict`

**Request:**
```json
{
  "model_id": "evo2_1b",
  "mutations": [
    {
      "gene": "TP53",
      "hgvs_p": "p.Arg175His",
      "chrom": "17",
      "pos": 7577120,
      "ref": "G",
      "alt": "A",
      "build": "GRCh37"
    }
  ],
  "disease": "ovarian_cancer",
  "options": {
    "adaptive": true,
    "ensemble": false
  },
  "tumor_context": {
    "disease": "ovarian_cancer"
  }
}
```

**Response Fields to Extract:**
- `drugs[0].efficacy_score` (top drug efficacy score)
- `drugs[0].confidence` (confidence score)
- `drugs[].name` (drug rankings)
- `provenance.confidence_breakdown.pathway_disruption` (pathway scores)
- `provenance.confidence_breakdown.S_contribution` (sequence contribution)
- `provenance.confidence_breakdown.P_contribution` (pathway contribution)
- `provenance.confidence_breakdown.E_contribution` (evidence contribution)

### **Output Format**

**File**: `data/benchmarks/cbioportal_benchmark_results_YYYYMMDD_HHMMSS.json`

**Structure:**
```json
{
  "timestamp": "2025-01-27T...",
  "benchmark_type": "clinical_trial_outcomes_cbioportal",
  "study_id": "ov_tcga_pan_can_atlas_2018",
  "metrics": {
    "pfs_correlation": {
      "pearson_r": 0.55,
      "spearman_rho": 0.52,
      "p_value": 0.001,
      "n_patients": 409
    },
    "os_correlation": {
      "pearson_r": 0.48,
      "spearman_rho": 0.45,
      "p_value": 0.005,
      "n_patients": 409
    },
    "response_classification": {
      "roc_auc": 0.68,
      "sensitivity": 0.72,
      "specificity": 0.65,
      "n_patients": 409
    },
    "survival_analysis": {
      "pfs_hr": 1.45,
      "pfs_p_value": 0.01,
      "os_hr": 1.38,
      "os_p_value": 0.02
    },
    "drug_ranking_accuracy": {
      "top_1_accuracy": 0.45,
      "top_3_accuracy": 0.72,
      "n_patients": 409
    }
  },
  "targets": {
    "pfs_correlation": {"min_pearson_r": 0.50},
    "os_correlation": {"min_pearson_r": 0.45},
    "response_classification": {"min_roc_auc": 0.65},
    "survival_analysis": {"min_hr": 1.3},
    "drug_ranking_accuracy": {"min_top_3": 0.70}
  },
  "results": [
    {
      "patient_id": "TCGA-04-1331",
      "mutations": ["TP53 p.Arg175His"],
      "actual_pfs_months": 15.09,
      "actual_pfs_status": "1:PROGRESSION",
      "actual_os_months": 43.92,
      "actual_os_status": "1:DECEASED",
      "our_efficacy_score": 0.82,
      "our_top_drug": "olaparib",
      "our_rank": 1,
      "actual_treatments": ["Carboplatin"],
      "correlation_status": "‚úÖ PASS"
    }
  ],
  "provenance": {
    "script": "benchmark_clinical_trial_outcomes_cbioportal.py",
    "dataset_source": "cbioportal",
    "study_id": "ov_tcga_pan_can_atlas_2018",
    "api_base": "http://127.0.0.1:8000",
    "model_id": "evo2_1b",
    "extraction_date": "2025-01-27T12:31:11"
  }
}
```

---

## ‚úÖ **QUALITY ASSURANCE CHECKLIST**

- [x] ‚úÖ Data availability thoroughly tested
- [x] ‚úÖ All required fields confirmed available
- [x] ‚úÖ Extraction script created with error handling
- [x] ‚úÖ Data validation logic implemented
- [x] ‚úÖ Quality checks implemented
- [x] ‚úÖ Benchmarking readiness assessment implemented
- [x] ‚úÖ Documentation comprehensive
- [x] ‚úÖ Script syntax validated
- [x] ‚úÖ **Extraction completed successfully**
- [x] ‚úÖ **409 patients ready for benchmarking** (exceeds 200 minimum)
- [x] ‚úÖ **No quality issues detected**
- [x] ‚úÖ Benchmark script created
- [ ] ‚è≥ Benchmark results computed (ready to run)
- [ ] ‚è≥ Results validated

---

**Status**: ‚úÖ **EXTRACTION COMPLETE - BENCHMARKING READY**

**Next**: Create benchmark script to run predictions and compute correlation metrics

